IL15 and neoplasm: Our data show that a vaccine consisting of a recombinant adenovirus with a target antigen transgene coupled with an IL-15 super agonist adjuvant is able to contribute to checkpoint-based immunotherapy by increasing T-cell migration to the tumor, enhancing T-cell activation and cytotoxicity, and promoting TCR diversity and antigen cascade.